Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Parathyroid hormone assays and their clinical use

Ghada El-Hajj Fuleihan, MD, MPH
Harald Jüppner, MD
Section Editor
Clifford J Rosen, MD
Deputy Editor
Jean E Mulder, MD


Parathyroid hormone 1-84 (PTH[1-84]) is the biologically active hormone produced by the parathyroid glands and secreted into the systemic circulation. It exerts its effects through the interaction of its first 34 amino acids with the type 1 PTH/PTHrP receptor (PTHR1). PTH fragments, containing carboxyl-(C) or amino-terminal (N-terminal) portions of the molecule that arise from either intraglandular or peripheral degradation of the hormone, are also present in the circulation.

PTH(1-84) has a plasma half-life of two to four minutes. In comparison, the C-terminal fragments, which are cleared principally by the kidney, have a half-life that is 5 to 10 times longer. As a result, circulating immunoreactive PTH in normocalcemic subjects comprises:

PTH(1-84) – 5 to 30 percent

C-terminal fragments – 70 to 95 percent

N-terminal fragments – a small percentage

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Jan 05, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev 2005; 26:78.
  2. Hocher B, Armbruster FP, Stoeva S, et al. Measuring parathyroid hormone (PTH) in patients with oxidative stress--do we need a fourth generation parathyroid hormone assay? PLoS One 2012; 7:e40242.
  3. Berson SA, Yalow RS, Aurbach GD, Potts JT. IMMUNOASSAY OF BOVINE AND HUMAN PARATHYROID HORMONE. Proc Natl Acad Sci U S A 1963; 49:613.
  4. Segre GV, Potts JT Jr. Differential diagnosis of hypercalcemia. In: Endocrinology, DeGroot LJ (Ed), WB Saunders, Philadelphia 1995. p.1075.
  5. Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33:1364.
  6. Goodman WG, Jüppner H, Salusky IB, Sherrard DJ. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int 2003; 63:1.
  7. Martin KJ, Akhtar I, González EA. Parathyroid hormone: new assays, new receptors. Semin Nephrol 2004; 24:3.
  8. Ekins R. More sensitive immunoassays. Nature 1980; 284:14.
  9. Brossard JH, Cloutier M, Roy L, et al. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996; 81:3923.
  10. Lepage R, Roy L, Brossard JH, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44:805.
  11. Brossard JH, Lepage R, Cardinal H, et al. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000; 46:697.
  12. D'Amour P, Brossard JH, Rousseau L, et al. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003; 49:2037.
  13. D'Amour P, Brossard JH, Räkel A, et al. Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem 2005; 51:169.
  14. John MR, Goodman WG, Gao P, et al. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999; 84:4287.
  15. Divieti P, John MR, Jüppner H, Bringhurst FR. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002; 143:171.
  16. Gao P, Scheibel S, D'Amour P, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001; 16:605.
  17. Slatopolsky E, Finch J, Clay P, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58:753.
  18. Salusky IB, Goodman WG, Kuizon BD, et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003; 63:1801.
  19. Savoca R, Bock A, Kraenzlin ME, et al. An automated 'bio-intact' PTH assay: a step towards standardisation and improved correlation with parathyroid function in renal disease. Clin Chim Acta 2004; 343:167.
  20. Hecking M, Kainz A, Bielesz B, et al. Clinical evaluation of two novel biointact PTH(1-84) assays in hemodialysis patients. Clin Biochem 2012; 45:1645.
  21. Tan K, Ong L, Sethi SK, Saw S. Comparison of the Elecsys PTH(1-84) assay with four contemporary second generation intact PTH assays and association with other biomarkers in chronic kidney disease patients. Clin Biochem 2013; 46:781.
  22. Souberbielle JC, Massart C, Brailly-Tabard S, et al. Serum PTH reference values established by an automated third-generation assay in vitamin D-replete subjects with normal renal function: consequences of diagnosing primary hyperparathyroidism and the classification of dialysis patients. Eur J Endocrinol 2016; 174:315.
  23. Cavalier E, Delanaye P, Nyssen L, Souberbielle JC. Problems with the PTH assays. Ann Endocrinol (Paris) 2015; 76:128.
  24. www.ifcc.org/ifcc-scientific-division/sd-working-groups/parathyroid-hormone-wg-pth/ (Accessed on December 29, 2015).
  25. Joly D, Drueke TB, Alberti C, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008; 51:987.
  26. Levin O, Morris LF, Wah DT, et al. Falsely elevated plasma parathyroid hormone level mimicking tertiary hyperparathyroidism. Endocr Pract 2011; 17:e8.
  27. Cavalier E, Delanaye P, Hubert P, et al. Estimation of the stability of parathyroid hormone when stored at -80 degrees C for a long period. Clin J Am Soc Nephrol 2009; 4:1988.
  28. Cavalier E, Carlisi A, Bekaert AC, et al. New insights on the stability of the parathyroid hormone as assayed by an automated 3rd generation PTH assay. Clin Chim Acta 2012; 413:353.
  29. D'Amour P. Circulating PTH molecular forms: what we know and what we don't. Kidney Int Suppl 2006; :S29.
  30. D'Amour P, Brossard JH, Rousseau L, et al. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005; 68:998.
  31. Kunii IS, Vieira JG. Circulating forms of parathyroid hormone detected with an immunofluorometric assay in patients with primary hyperparathyroidism and in hyperparathyroidism secondary to chronic renal failure. Braz J Med Biol Res 2001; 34:1547.
  32. Räkel A, Brossard JH, Patenaude JV, et al. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol (Oxf) 2005; 62:721.
  33. Au AY, McDonald K, Gill A, et al. PTH mutation with primary hyperparathyroidism and undetectable intact PTH. N Engl J Med 2008; 359:1184.
  34. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:1516.
  35. Nguyen-Yamamoto L, Rousseau L, Brossard JH, et al. Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 2001; 142:1386.
  36. Inomata N, Akiyama M, Kubota N, Jüppner H. Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84). Endocrinology 1995; 136:4732.
  37. Demay M, Mitchell J, Goltzman D. Comparison of renal and osseous binding of parathyroid hormone and hormonal fragments. Am J Physiol 1985; 249:E437.
  38. McKee MD, Murray TM. Binding of intact parathyroid hormone to chicken renal plasma membranes: evidence for a second binding site with carboxyl-terminal specificity. Endocrinology 1985; 117:1930.
  39. Murray TM, Rao LG, Muzaffar SA. Dexamethasone-treated ROS 17/2.8 rat osteosarcoma cells are responsive to human carboxylterminal parathyroid hormone peptide hPTH (53-84): stimulation of alkaline phosphatase. Calcif Tissue Int 1991; 49:120.
  40. Rao LG, Murray TM. Binding of intact parathyroid hormone to rat osteosarcoma cells: major contribution of binding sites for the carboxyl-terminal region of the hormone. Endocrinology 1985; 117:1632.
  41. Divieti P, Inomata N, Chapin K, et al. Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells. Endocrinology 2001; 142:916.
  42. Langub MC, Monier-Faugere MC, Wang G, et al. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 2003; 144:1135.
  43. Wesseling-Perry K, Harkins GC, Wang HJ, et al. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin Endocrinol Metab 2010; 95:2772.
  44. Rubin MR, Silverberg SJ, D'Amour P, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem 2007; 53:1470.
  45. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49:1304.
  46. Hocher B, Oberthür D, Slowinski T, et al. Modeling of oxidized PTH (oxPTH) and non-oxidized PTH (n-oxPTH) receptor binding and relationship of oxidized to non-oxidized PTH in children with chronic renal failure, adult patients on hemodialysis and kidney transplant recipients. Kidney Blood Press Res 2013; 37:240.
  47. Laethem R, Zull JE. Characterization of the interaction of parathyroid hormone with the mitochondrial ATPase. Arch Biochem Biophys 1990; 282:161.
  48. Vogt W. Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic Biol Med 1995; 18:93.
  49. Silverberg SJ, Gao P, Brown I, et al. Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:4725.
  50. Cavalier E, Daly AF, Betea D, et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 2010; 95:3745.
  51. Lee S, Mannstadt M, Guo J, et al. A Homozygous [Cys25]PTH(1-84) Mutation That Impairs PTH/PTHrP Receptor Activation Defines a Novel Form of Hypoparathyroidism. J Bone Miner Res 2015; 30:1803.
  52. Bouillon R, Coopmans W, Degroote DE, et al. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem 1990; 36:271.
  53. Carnevale V, Dionisi S, Nofroni I, et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 2004; 50:626.
  54. Boudou P, Ibrahim F, Cormier C, et al. Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:6370.
  55. Silverberg SJ, Bilezikian JP. "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab 2003; 88:5348.
  56. Yamashita H, Gao P, Cantor T, et al. Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. Surgery 2004; 135:149.
  57. Yamashita H, Cantor T, Uchino S, et al. Sequential changes in plasma intact and whole parathyroid hormone levels during parathyroidectomy for secondary hyperparathyroidism. World J Surg 2005; 29:169.
  58. Monier-Faugere MC, Geng Z, Mawad H, et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60:1460.
  59. Kazama JJ, Omori T, Ei I, et al. Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia. Clin Exp Nephrol 2003; 7:144.
  60. Lehmann G, Stein G, Hüller M, et al. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005; 68:1206.
  61. Melamed ML, Eustace JA, Plantinga LC, et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008; 23:1650.
  62. Gannagé-Yared MH, Farès C, Ibrahim T, et al. Comparison between a second and a third generation parathyroid hormone assay in hemodialysis patients. Metabolism 2013; 62:1416.
  63. Donadio C, Ardini M, Lucchesi A, et al. Parathyroid hormone and large related C-terminal fragments increase at different rates with worsening of renal function in chronic kidney disease patients. A possible indicator of bone turnover status? Clin Nephrol 2007; 67:131.
  64. Herberth J, Fahrleitner-Pammer A, Obermayer-Pietsch B, et al. Changes in total parathyroid hormone (PTH), PTH-(1-84) and large C-PTH fragments in different stages of chronic kidney disease. Clin Nephrol 2006; 65:328.
  65. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure--an evolving disorder. Kidney Int 1993; 43:436.
  66. Salusky IB, Coburn JW, Brill J, et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 1988; 33:975.
  67. Coen G, Bonucci E, Ballanti P, et al. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40:348.
  68. Inaba M, Okuno S, Imanishi Y, et al. Significance of Bio-intact PTH(1-84) assay in hemodialysis patients. Osteoporos Int 2005; 16:517.
  69. Goodman WG. The evolution of assays for parathyroid hormone. Semin Dial 2005; 18:296.
  70. Negri AL, Alvarez Quiroga M, Bravo M, et al. [Whole PTH and 1-84/84 PTH ratio for the non invasive determination of low bone turnover in renal osteodysthrophy]. Nefrologia 2003; 23:327.
  71. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003; 18:759.
  72. Tepel M, Armbruster FP, Grön HJ, et al. Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients. J Clin Endocrinol Metab 2013; 98:4744.
  73. Hatakeyama Y, Mizunashi K, Furukawa Y, et al. Plasma levels of parathyroid hormone (1-84) whole molecule and parathyroid hormone (7-84)-like fragments in pseudohypoparathyroidism type I. J Clin Endocrinol Metab 2003; 88:2250.